Baxis Pharmaceutical, Inc.
Our vision
Introduce a novel class of ophthalmic antibiotic in the US as no new class has been developed in over 25 years. This would provide a well-established, first-line antibiotic that is new to the United States with proven safety, efficacy and low resistance rate with a novel MOA in a convenient dosing regimen and formulation.
Who we are
Baxis Pharmaceuticals is a portfolio company of PBM Capital Group focused on the development of a product for the treatment of topical ophthalmic infections. Baxis is currently running a Phase 3 Clinical Trial for Fucithalmic®, an antibiotic commercially available throughout the world to treat superficial eye infections.
Our Status
Fucithalmic® is currently under Phase 3 clinical study evaluation (clincaltrials.gov study details).
It is not currently available under expanded access.